Onyirioha Kristeen, Mittal Sukul, G Singal Amit
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Hepat Oncol. 2020 Jul 24;7(3):HEP25. doi: 10.2217/hep-2020-0012.
Several professional societies recommend hepatocellular carcinoma (HCC) surveillance in high-risk patients including patients with cirrhosis from any etiology and subsets of noncirrhotic chronic hepatitis B virus infection. The efficacy of HCC surveillance to increase early detection and improve survival has been demonstrated in a large randomized controlled trial among hepatitis B virus patients and several cohort studies among those with cirrhosis. However, the effectiveness on HCC surveillance, when applied in clinical practice, is lower due to low utilization of HCC surveillance among at-risk patients, poorer test performance given operator dependency and differences in patient characteristics, and downstream process failures such as treatment delays. Interventions to increase surveillance utilization and improve surveillance test performance should improve surveillance effectiveness in the future.
几个专业学会建议对高危患者进行肝细胞癌(HCC)监测,包括任何病因引起的肝硬化患者以及非肝硬化慢性乙型肝炎病毒感染亚组患者。HCC监测在提高早期检测率和改善生存率方面的有效性已在一项针对乙型肝炎病毒患者的大型随机对照试验以及几项针对肝硬化患者的队列研究中得到证实。然而,在临床实践中应用时,HCC监测的有效性较低,原因包括高危患者对HCC监测的利用率低、由于依赖操作人员以及患者特征差异导致检测性能较差,以及下游流程失败,如治疗延迟。未来,提高监测利用率和改善监测检测性能的干预措施应能提高监测有效性。